Company profile: Laronde
1.1 - Company Overview
Company description
- Provider of an eRNA-based therapeutic platform, offering Endless RNA to program protein expression for therapeutic use; proprietary Natural NanoParticle technology to deliver biomolecules into human cells, enabling diverse administration routes and re-dosing; and AI-driven drug development using proprietary algorithms for rapid RNA medicine design.
Products and services
- AI-driven drug development: Employs proprietary AI algorithms to design and rapidly prototype RNA medicines, enhancing performance and expanding applicability across various diseases
- Endless RNA (eRNA): Synthetic RNA technology that programs expression of diverse proteins within the body for therapeutic applications, enabling in-body protein induction with stable activity
- Natural NanoParticle (NNP) deployment technology: Proprietary nanoparticles derived from nature deliver biomolecules into human cells, allowing diverse administration routes and enabling re-dosing across therapeutic regimens
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Laronde
Regulus Therapeutics
HQ: United States
Website
- Description: Provider of microRNA-based therapeutics designed to inhibit dysregulated microRNA targets for genetically based orphan diseases, particularly orphan kidney diseases. Portfolio includes RGLS8429, a next-generation anti-miR-17 in Phase 1b for autosomal dominant polycystic kidney disease (ADPKD), supported by ongoing clinical trials to evaluate efficacy and safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Regulus Therapeutics company profile →
Nanogenics
HQ: United Kingdom
Website
- Description: Provider of research-based biotechnology developing artificial viruses for gene therapy. Products include LipTide, a synthetic peptide nanoparticle that mimics natural viruses for targeted RNA delivery to various cell types with low toxicity and repeat dosing, and ECP-105, a glaucoma therapy enhancing trabeculectomy by increasing bleb survival and reducing scarring with a single administration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nanogenics company profile →
Kate Therapeutics
HQ: United States
Website
- Description: Provider of AAV-based gene therapies targeting genetically defined muscle and heart diseases, supported by the DELIVER capsid engineering platform for evolving tissue-targeted AAV variants, MyoAAV muscle-tropic capsids for skeletal and cardiac delivery, and cargo technologies to enhance regulation, targeting, and safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kate Therapeutics company profile →
CRISPR Therapeutics
HQ: United States
Website
- Description: Provider of a proprietary CRISPR/Cas9 gene-editing platform and therapies to treat serious diseases, including CASGEVY™ (exagamglogene autotemcel), approved in some countries for sickle cell disease and transfusion-dependent beta thalassemia; CTX112, an investigational allogeneic CD19 CAR T therapy; and ex vivo and in vivo gene-editing and cell therapy approaches using viral and non-viral delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CRISPR Therapeutics company profile →
Exicure
HQ: United States
Website
- Description: Provider of a new class of immunomodulatory and gene silencing drugs against validated targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exicure company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Laronde
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Laronde
2.2 - Growth funds investing in similar companies to Laronde
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Laronde
4.2 - Public trading comparable groups for Laronde
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →